Eli Lilly and Company

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse Other stock markets 00:00:02 14/02/2026 +03			5-day change	1st Jan Change
1,040.00 ^USD	+0.33%		-1.72%	-3.23%

02-14	Soros Fund Management cuts share stake in Alphabet, raises share stake in Apple, Uber	RE
02-13	US could take action including fines against Hims after brief Wegovy copy launch	RE

Eli Lilly's weight-loss pill targeted by FDA for April 10, 2026 decision date - documents

Published on 01/15/2026 at 02:02 pm +03

Reuters

Latest news about Eli Lilly and Company

02-14	Soros Fund Management cuts share stake in Alphabet, raises share stake in Apple, Uber	RE
02-13	US could take action including fines against Hims after brief Wegovy copy launch	RE
02-13	AlphaValue/Baader Europe Cuts Novo Nordisk Price Target, Forecasts Amid Outlook Downgrades, Competitive Pressures	MT
02-13	Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision	RE
02-12	Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision	RE
02-12	Tranche Update on Eli Lilly and Company's Equity Buyback Plan announced on December 9, 2024.	CI
02-12	West Pharma forecasts 2026 profit above estimates on strong demand for drug components	RE
02-12	West Pharma forecasts 2026 profit above estimates on strong demand for drug components	RE
02-12	West Pharma forecasts 2026 profit above estimates on strong demand for drug components	RE
02-12	Novo Nordisk plans to launch Wegovy vials	RE
02-12	More than a third of patients on Wegovy pill are new to GLP-1 drugs, study finds	RE
02-11	More than a third of patients on Wegovy pill are new to GLP-1 drugs, study finds	RE
02-11	Pharma companies left out of Trump's drug-pricing deals look for way in	RE
02-11	Pharma companies left out of Trump's drug-pricing deals look for way in	RE
02-11	CICC Adjusts Price Target on Eli Lilly and Co. to $1,107 From $1,060, Maintains Neutral Rating	MT

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (65.5%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.4%); - immunology diseases (9.8%); - neurology (3.3%): primarily drugs used in treating depression and schizophrenia; - other (2%). Net sales are distributed geographically as follows: the United States (67.4%), Europe (15.4%), Japan (4%), China (3.7%) and other (9.5%).

Employees

50,000

Sector

Pharmaceuticals

Calendar

04-30 - Q1 2026 Earnings Release

More about the company